CR9957A - Uso de un anatagonista de cb1 para tratar efectos secundarios y sintomas negativos de la esquizofrenia - Google Patents

Uso de un anatagonista de cb1 para tratar efectos secundarios y sintomas negativos de la esquizofrenia

Info

Publication number
CR9957A
CR9957A CR9957A CR9957A CR9957A CR 9957 A CR9957 A CR 9957A CR 9957 A CR9957 A CR 9957A CR 9957 A CR9957 A CR 9957A CR 9957 A CR9957 A CR 9957A
Authority
CR
Costa Rica
Prior art keywords
negative symptoms
combination
chichophrenia
anatagonist
secondary effects
Prior art date
Application number
CR9957A
Other languages
English (en)
Inventor
Black Mark
Browsky Beth
Rogacki Nancy
Senyah Yaw
Stevens Rachel
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of CR9957A publication Critical patent/CR9957A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion describe y reivindica un metodo para tratar deficits cognitivos en un paciente que padece esquizofrenia, mediante la adminsitracion a dicho paciente de una cantidad terapeuticamente eficaz de un antagonista del receptor CB1 como se describe en est amemoria. En otro aspecto, esta invencion tambien describe y reivindica una combinacion de uno o mas antagonistas del receptor CB1 y de uno o mas agentes antipsicoticos utiles en el tratamiento de trastornos psiquiatricos. La combinacion de esta invencion proporciona resultados sinergicos en los que la combinacion mejora los sintomas positivos y negativos de la esquizofrenia, la ganancia de peso y la catalepsia.
CR9957A 2005-12-08 2008-05-07 Uso de un anatagonista de cb1 para tratar efectos secundarios y sintomas negativos de la esquizofrenia CR9957A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74843405P 2005-12-08 2005-12-08

Publications (1)

Publication Number Publication Date
CR9957A true CR9957A (es) 2008-09-22

Family

ID=37964962

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9957A CR9957A (es) 2005-12-08 2008-05-07 Uso de un anatagonista de cb1 para tratar efectos secundarios y sintomas negativos de la esquizofrenia

Country Status (23)

Country Link
US (1) US20080221078A1 (es)
EP (1) EP1962834A2 (es)
JP (1) JP2009518423A (es)
KR (1) KR20080073737A (es)
CN (1) CN101321523A (es)
AR (1) AR056846A1 (es)
AU (1) AU2006321907A1 (es)
BR (1) BRPI0619541A2 (es)
CA (1) CA2632673A1 (es)
CR (1) CR9957A (es)
DO (1) DOP2006000273A (es)
EC (1) ECSP088505A (es)
IL (1) IL191888A0 (es)
MA (1) MA30090B1 (es)
NO (1) NO20082923L (es)
PE (1) PE20071092A1 (es)
RU (1) RU2008127491A (es)
SV (1) SV2008002929A (es)
TN (1) TNSN08205A1 (es)
TW (1) TW200803839A (es)
UY (1) UY29995A1 (es)
WO (1) WO2007067617A2 (es)
ZA (1) ZA200803924B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
WO2007118854A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
WO2008124118A1 (en) 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
WO2009040659A2 (en) 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
JP2010540629A (ja) * 2007-10-04 2010-12-24 メルク・シャープ・エンド・ドーム・コーポレイション カルシウムチャネル遮断薬としての置換アリールスルホン誘導体
FR2925051B1 (fr) * 2007-12-18 2010-05-21 Sanofi Aventis Derives d'azetidines,leur preparation et leur application en therapeutique
EP2234966B1 (fr) * 2007-12-18 2013-09-11 Sanofi Derives d'azetidines, leur preparation et leur application en therapeutique
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
WO2010079241A1 (es) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
EP3180335B1 (en) 2014-08-11 2021-05-05 Angion Biomedica Corporation Cytochrome p450 inhibitors and uses thereof
BR112017004612A2 (pt) * 2014-09-10 2018-01-30 Epizyme, Inc. compostos, composição farmacêutica, usos de um composto, e kit
CA2970819A1 (en) 2014-12-31 2016-07-07 Angion Biomedica Corp. Methods and agents for treating disease
EP4516356A3 (en) 2016-08-24 2025-05-14 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355631B1 (en) * 2000-03-03 2002-03-12 Aventis Pharma S.A. Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
US6566356B2 (en) * 2000-03-03 2003-05-20 Aventis Pharma S.A. Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
US6479479B2 (en) * 2000-03-03 2002-11-12 Aventis Pharma S.A. Azetidine derivatives, their preparation and pharmaceutical compositions containing them
CN1802351A (zh) * 2003-06-11 2006-07-12 麦克公司 被取代的3－烷基和3－链烯基氮杂环丁烷衍生物
EP1663215A1 (en) * 2003-09-02 2006-06-07 Solvay Pharmaceuticals GmbH Novel medical use of selective cb1- receptor antagonists
WO2006017892A1 (en) * 2004-08-16 2006-02-23 Northern Sydney And Central Coast Area Health Service Methods for improving cognitive functioning
FR2882931B1 (fr) * 2005-03-14 2007-05-18 Sanofi Aventis Sa Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoidess et un agent antipsychotique

Also Published As

Publication number Publication date
TW200803839A (en) 2008-01-16
CN101321523A (zh) 2008-12-10
JP2009518423A (ja) 2009-05-07
PE20071092A1 (es) 2007-12-10
US20080221078A1 (en) 2008-09-11
ZA200803924B (en) 2009-10-28
SV2008002929A (es) 2009-12-02
EP1962834A2 (en) 2008-09-03
MA30090B1 (fr) 2008-12-01
IL191888A0 (en) 2009-08-03
TNSN08205A1 (en) 2009-10-30
NO20082923L (no) 2008-09-02
DOP2006000273A (es) 2007-10-15
UY29995A1 (es) 2007-07-31
WO2007067617A2 (en) 2007-06-14
AU2006321907A1 (en) 2007-06-14
WO2007067617A3 (en) 2007-11-01
ECSP088505A (es) 2008-08-29
RU2008127491A (ru) 2010-01-20
AR056846A1 (es) 2007-10-24
CA2632673A1 (en) 2007-06-14
KR20080073737A (ko) 2008-08-11
BRPI0619541A2 (pt) 2011-10-04

Similar Documents

Publication Publication Date Title
CR9957A (es) Uso de un anatagonista de cb1 para tratar efectos secundarios y sintomas negativos de la esquizofrenia
ECSP11011019A (es) Antagonistas del receptor de orexina de isonicotinamida
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
CY1110882T1 (el) Ανταγωνιστες υποδοχεων ορεξινης υποκατεστημενης διαζεπανης
EA201690033A2 (ru) Морфинановые соединения
CO6290684A2 (es) Inhibidores de actividad de proteina tirosina quinasa
GT200800265A (es) Pirido (3,2-e)piracinas, su uso como inhibidores de fosfadiesterasa 10, y procesos para prepararlas.
GT200900300A (es) Antagonistas piridil piperidina del receptor de orexina
CL2008002864A1 (es) Compuestos derivados de 2-amino-quinolina, antagonistas del receptor de serotonina 5-ht 5a; procedimiento de preparacion;composicion farmaceutica; y uso de los compuestos en la prevencion o el tratamiento de depresion,trastornos de ansiedad,esquizofrenia,trastornos de panico,trastornos de memoria,demencia,entre otros.
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
ECSP067116A (es) Antagonistas del receptor 2 de citocina quimioatrayente de sales cuaternarias
BRPI0411699A (pt) compostos para uso como substáncia terapeuticamente ativa; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação de receptores cb1 e uso destes compostos
DE602006019304D1 (de) Spirohydantoin-aryl-cgrp-rezeptorantagonisten
ECSP034811A (es) Derivados heterocicliloxi-, -tioxi - y - aminobenzazole tales como ligandos 5-hidroxitriptamina-6
ECSP088619A (es) Combinación de un inhibidor de acetilcolinesterasa y un antagonista de 5-ht6 para el tratamiento de la disfunción cognitiva
CL2007002899A1 (es) Compuestos derivados de azaciclilaminas n-sustituidas, inhibidores del receptor de histamina 3; proceso de preparacion; composicion farmaceutica que comprende los compuestos, y usopara el tratamiento de trastornos cognitivos, esquizofre nia y enfermedad de alzheimer entre otros.
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
SV2006002342A (es) Terapia de antiogenesis para enfermedades autoinmunes en pacientes que tuvieron la terapia anterior interrumpida
HN2003000080A (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso
CL2023001325A1 (es) Compuestos y su uso en el tratamiento de trastornos mediados por receptores de taquicinina
ATE478856T1 (de) Spirobenzodioxole und deren verwendung als cb1- antagonisten
UY27680A1 (es) Agonistas del receptor b3 - andrenérgicos.
GB2470495A (en) Oxazolidine derivatives as NMDA antagonists
UY32005A (es) Derivados de estratrieno que comprenden bioisósteros heterocíclicos para el anillo fenólico a
ATE507830T1 (de) Verwendung von antagonisten von oxytocin und/oder vasopressin bei der assistierten fortpflanzung

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)